---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-260640"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2026-06-08T10:32:15+00:00"
generated_at: "2026-06-08T10:35:18.201722+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cullinan presents initial Phase 1 CLN-978 data in SLE and RA at EULAR; 71% SLE response rate, 5 DORIS remissions

## Summary
- In SLE (n=18), 10 of 14 patients (71%) with ≥4 weeks follow-up achieved ≥4-point hSLEDAI reduction; 5 attained DORIS remission.
- In RA (n=11), disease activity improved in 5 of 7 evaluable patients (71%), including one DAS28-ESR remission at 30 µg target dose.
- Peripheral B-cell depletion >80% in 82% of SLE patients; BLOQ depletion in 50% at target doses ≥20 µg. Dose-dependent depletion also seen in tissues.
- CRS events in 11 of 29 patients (38%); mostly Grade 1. One Grade 3 CRS at 45 µg dose led to cohort discontinuation; no ICANS observed.
- Company to host Immunology Day June 10 with additional CLN-978 multi-dose data and initial velinotamig data.

## SEC filing metadata
- accession: 0001193125-26-260640
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2026-06-08T10:32:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312526260640/0001193125-26-260640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312526260640/cgem-20260606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-260640
- JSON: https://secwatch.observer/filing/0001193125-26-260640.json
- Plain text: https://secwatch.observer/filing/0001193125-26-260640.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.